VERTEX PHARMACEUTICALS INC / MA Tax Withholding Paid on Stock Awards
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Tax Withholding Paid on Stock Awards of $232.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $4.30M, a 27.12% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $228.50M, a 15.53% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $2.50M, a 65.75% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $91.00M, a 8.72% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA payment, tax withholding, share-based payment arrangement for fiscal 2025 was $369.90M, a 8.67% decline from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA payment, tax withholding, share-based payment arrangement for fiscal 2024 was $405.00M, a 79.12% increase from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA payment, tax withholding, share-based payment arrangement for fiscal 2023 was $226.10M, a 31.45% increase from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA payment, tax withholding, share-based payment arrangement for fiscal 2022 was $172.00M, a 26.56% increase from fiscal 2021.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 3 month as first filed | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month as first filed | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month as first filed | Payment, Tax Withholding, Share-based Payment Arrangement 12 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $232.80M 10-Q · filed 2026-08-04 | $235.30M derived: sum of 3 quarters · filed 2026-08-04 | $326.30M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $228.50M 10-Q · filed 2026-05-05 | $231.00M derived: sum of 2 quarters · filed 2026-05-05 | $322.00M derived: sum of 3 quarters · filed 2026-05-05 | $327.90M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $93.50M derived: sum of 2 quarters · filed 2026-02-13 | $99.40M derived: sum of 3 quarters · filed 2026-08-04 | $369.90M 10-K · filed 2026-02-13 | ||||
| 2025-09-30 | $91.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $96.90M derived: sum of 2 quarters · filed 2026-08-04 | $367.40M 10-Q · filed 2025-11-04 | $374.70M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $5.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $276.40M 10-Q · filed 2026-08-04 | $283.70M derived: sum of 3 quarters · filed 2026-08-04 | $367.40M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $270.50M 10-Q · filed 2026-05-05 | $277.80M derived: sum of 2 quarters · filed 2026-05-05 | $361.50M derived: sum of 3 quarters · filed 2026-05-05 | $442.00M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $7.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $91.00M derived: sum of 2 quarters · filed 2026-02-13 | $171.50M derived: sum of 3 quarters · filed 2026-02-13 | $405.00M 10-K · filed 2026-02-13 | ||||
| 2024-09-30 | $83.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $164.20M derived: sum of 2 quarters · filed 2025-11-04 | $397.70M 10-Q · filed 2025-11-04 | $400.90M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-06-30 | $80.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $314.00M 10-Q · filed 2025-08-05 | $317.20M derived: sum of 3 quarters · filed 2026-02-13 | $370.40M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-03-31 | $233.50M 10-Q · filed 2025-05-06 | $236.70M derived: sum of 2 quarters · filed 2026-02-13 | $289.90M derived: sum of 3 quarters · filed 2026-02-13 | $293.00M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2023-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $56.40M derived: sum of 2 quarters · filed 2026-02-13 | $59.50M derived: sum of 3 quarters · filed 2026-02-13 | $226.10M 10-K · filed 2026-02-13 | ||||
| 2023-09-30 | $53.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $56.30M derived: sum of 2 quarters · filed 2024-11-05 | $222.90M 10-Q · filed 2024-11-05 | $225.00M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-06-30 | $3.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $169.70M 10-Q · filed 2024-08-02 | $171.80M derived: sum of 3 quarters · filed 2025-02-13 | $219.80M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-03-31 | $166.60M 10-Q · filed 2024-05-07 | $168.70M derived: sum of 2 quarters · filed 2025-02-13 | $216.70M derived: sum of 3 quarters · filed 2025-02-13 | $221.10M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2022-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $50.10M derived: sum of 2 quarters · filed 2025-02-13 | $54.50M derived: sum of 3 quarters · filed 2025-02-13 | $172.00M 10-K · filed 2025-02-13 | ||||
| 2022-09-30 | $48.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $52.40M derived: sum of 2 quarters · filed 2023-11-07 | $169.90M 10-Q · filed 2023-11-07 | $171.60M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-06-30 | $4.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $121.90M 10-Q · filed 2023-08-02 | $123.60M derived: sum of 3 quarters · filed 2024-02-15 | $152.10M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-03-31 | $117.50M 10-Q · filed 2023-05-02 | $119.20M derived: sum of 2 quarters · filed 2024-02-15 | $147.70M derived: sum of 3 quarters · filed 2024-02-15 | $151.30M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2021-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $30.20M derived: sum of 2 quarters · filed 2024-02-15 | $33.80M derived: sum of 3 quarters · filed 2024-02-15 | $135.90M 10-K · filed 2024-02-15 | ||||
| 2021-09-30 | $28.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $32.10M derived: sum of 2 quarters · filed 2022-10-28 | $134.20M 10-Q · filed 2022-10-28 | $134.22M 10-Q · filed 2021-11-03 | $154.72M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2021-06-30 | $3.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $105.70M 10-Q · filed 2022-08-05 | $105.66M 10-Q · filed 2021-07-30 | $126.22M derived: sum of 3 quarters · filed 2023-02-10 | $166.75M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2021-03-31 | $102.10M 10-Q · filed 2022-05-06 | $102.14M 10-Q · filed 2021-04-30 | $122.63M derived: sum of 2 quarters · filed 2023-02-10 | $163.15M derived: sum of 3 quarters · filed 2023-02-10 | $166.23M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2020-12-31 | $20.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $61.05M derived: sum of 2 quarters · filed 2023-02-10 | $64.13M derived: sum of 3 quarters · filed 2023-02-10 | $200.30M 10-K · filed 2023-02-10 | $200.27M 10-K · filed 2021-02-11 | |||
| 2020-09-30 | $40.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $43.61M derived: sum of 2 quarters · filed 2021-11-03 | $179.78M 10-Q · filed 2021-11-03 | $179.84M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-06-30 | $3.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $139.25M 10-Q · filed 2021-07-30 | $139.31M derived: sum of 3 quarters · filed 2022-02-09 | $139.41M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-03-31 | $136.17M 10-Q · filed 2021-04-30 | $136.23M derived: sum of 2 quarters · filed 2022-02-09 | $136.34M derived: sum of 3 quarters · filed 2022-02-09 | $136.34M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2019-12-31 | $64.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $168.00K derived: sum of 2 quarters · filed 2022-02-09 | $168.00K derived: sum of 3 quarters · filed 2022-02-09 | $6.00M 10-K · filed 2022-02-09 | $6.00M 10-K · filed 2021-02-11 | |||
| 2019-09-30 | $104.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $104.00K derived: sum of 2 quarters · filed 2020-10-30 | $5.94M 10-Q · filed 2020-10-30 | |||||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $5.83M 10-Q · filed 2020-07-31 | ||||||
| 2019-03-31 | $5.83M 10-Q · filed 2020-05-01 | |||||||
| 2018-12-31 | $0.00 10-K · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |